Disease relevance of Dipiperal

• Response to pipamperone in case of epidermolysis bullosa herpetiformis [1].
• This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone [2].
• Torsade de pointes after pipamperone intoxication [3].
• Toxicity of synthetic piperonyl compounds to leaf-cutting ants and their symbiotic fungus [4].
• Neither floropipamide, a dopamine antagonist, nor bromocriptine, a dopamine agonist, affected the b-wave recovery after ischemia [5].

Psychiatry related information on Dipiperal

• Pipamperone was compared double-blindly with placebo to evaluate its capacity to relieve sleep disorders in 40 depressive inpatients [6].

High impact information on Dipiperal

• The sequence involves the synthesis of NCA p-[18F]fluorobenzonitrile from NCA [18F]-fluoride and p-nitrobenzonitrile using the rapidly converted to gamma-chloro-p-[18F]fluorobutyrophenone which is alkylated with appropriate amines to give NCA 18F-labeled benperidol, haloperidol, spiroperidol, and pipamperone [7].
• In vivo, ORG-5222, risperidone, pipamperone, 9-OH-risperidone, sertindole, olanzapine, zotepine and clozapine maintained a higher potency for occupying 5HT2A than D2 receptors [8].
• Three drugs with a 1000-fold selectivity for the 5-HT2 binding site (ketanserin, ritanserin, pipamperone) increased the reinforcement rate and decreased the response rate similar to antidepressant drugs [9].
• Different regulation of rat 5-HT(2A) and rat 5-HT(2C) receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone [10].
• Esterase inhibition and reactivation in relation to piperonyl butoxide-phosphorothionate interactions [11].

Biological context of Dipiperal

• Pharmacokinetics of pipamperone from three different tablet formulations [12].
• Floropipamide had little effect on the intraocular pressure (IOP), yet it reduced the ocular blood flow markedly [13].
• In amphetamine-challenged rats pipamperone-like activity is reflected in preferential inhibition of the excessive oxygen consumption rather than of agitation [14].
• Piperonyl butoxid, a radical scavenger, protected against CCl4-induced inhibition of lipoprotein section, lipid peroxidation and covalent binding [15].
• A good correlation (r2=0.970) was observed between the -log IC50 values of the tested compounds and their piperonyl butoxide-synergised insecticidal activities (-log LD50 values) against German cockroaches [16].

Anatomical context of Dipiperal

• Pimozide (0.04, 0.16, 0.63 and 2.50 mg/kg), haloperidol (0.01, 0.04, 0.16 and 0.63 mg/kg) and pipamperone (2.50, 10.0, 40.0 and 160 mg/kg) were given subcutaneously to rats, pressing a lever for brain-stimulation through electrodes implanted in the lateral hypothalamic region of the medial forebrain bundle [17].

Associations of Dipiperal with other chemical compounds

• We used either specific inhibitors of peroxidases (i.e. salicylhydroxamic acid) and of cytochrome P-450 (i.e. piperonyl butoxyde) or inhibitors of both enzymes (i.e. potassium cyanide) [18].
• The three compounds in whole blood could be actually determined 3 and 6 h after oral administration of 1 mg each of haloperidol and bromperidol, and 10 mg of floropipamide in a volunteer [19].
• In each treatment phase, subjects received a single dose of 144 mg pipamperone dihydrochloride (CAS 2448-68-2) (equivalent to 120 mg pipamperone; CAS 1893-33-0) as either the reference product (3 x 40 mg tablets), test product A (3 x 40 mg tablets) or test product B (1 x 120 mg tablet) [12].

Gene context of Dipiperal

• The electrochemical reduction of pipamperone has been carried out in aqueous solution in KNO(3) (0.1 mol l(-1)) by differential-pulse polarography (DPP) [20].
• A sensitive and reproducible high performance liquid chromatographic method was developed for the determination of pipamperone (1'-[4-(4-fluorophenyl)-4-oxobutyl]-[1,4'-bipiperidine]-4'- carboxamide, Dipiperon, CAS 1893-33-0) in plasma samples [21].

Analytical, diagnostic and therapeutic context of Dipiperal

• Mass spectral characterization of urinary pipamperone metabolites and high-performance liquid chromatography assay for pipamperone plasma levels [22].
• A 6-week double-blind cross-over study comparing pipamperone with placebo was conducted in 20 female mental retardates with behavioural disorders [23].
• At the end of the 1-week trial, most of the items relating to sleep disturbances had improved significantly in the 24 patients of the pipamperone group whereas only a few items showed such a change in the control group [6].
• Differential-pulse polarography determination of pipamperone in pharmaceutical formulations [20].

References